LC
FLNA

Lindbrook Capital’s Filana Therapeutics FLNA Stock Holding History

Lindbrook Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-96
Closed -$227 – 2914
2024
Q4 		$227 Sell
96
-1
-1% -$18 ﹤0.01% 2710
2024
Q3 		$2.85K Sell
97
-18
-16% -$415 ﹤0.01% 2236
2024
Q2 		$1.42K Hold
115
– – ﹤0.01% 2434
2024
Q1 		$2.33K Hold
115
– – ﹤0.01% 2188
2023
Q4 		$2.59K Sell
115
-16
-12% -$338 ﹤0.01% 2177
2023
Q3 		$2.18K Buy
131
+71
+118% +$1.41K ﹤0.01% 2091
2023
Q2 		$1.47K Sell
60
-30
-33% -$723 ﹤0.01% 2267
2023
Q1 		$2.17K Sell
90
-319
-78% -$8.84K ﹤0.01% 2211
2022
Q4 		$12.1K Buy
409
+48
+13% +$1.73K ﹤0.01% 1340
2022
Q3 		$15K Buy
361
+282
+357% +$7.62K ﹤0.01% 1140
2022
Q2 		$2K Buy
79
+38
+93% +$960 ﹤0.01% 2047
2022
Q1 		$2K Buy
+41
New +$1.74K ﹤0.01% 2074

Other funds holding FLNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lindbrook Capital's FLNA Position: Q1 2025 in Review

Lindbrook Capital sold out of Filana Therapeutics (FLNA) in Q1 2025, closing a stake of 96 shares — an estimated $227 sold.

Lindbrook Capital first reported a position in FLNA in Q1 2022 and held it in 12 quarters. The position peaked at $15K in Q3 2022. 117 funds tracked by Wall St. Rank hold FLNA as of Q1 2025.

  • Lindbrook Capital reported no remaining Filana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 96 Filana Therapeutics shares in Q1 2025, an estimated $227.
  • Lindbrook Capital first reported a position in Filana Therapeutics in Q1 2022 and held it in 12 quarters.
  • Lindbrook Capital's Filana Therapeutics position peaked at $15K in Q3 2022.
  • 117 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.